Maxim Group Maintains RenovoRx(RNXT.US) With Buy Rating, Maintains Target Price $4

Futu NewsNov 15 23:31 · Ratings

Positive Outlook for RenovoRx: Promising TIGeR-PaC Phase 3 Trial Results and Innovative Drug Delivery Platform Drive Buy Rating

TipRanksNov 15 23:15 · Ratings

RenovoRx Q3 EPS $(0.10), Inline

BenzingaNov 14 21:23

Express News | RenovoRx Q3 Net Income USD -2.5 Million

BreakingsNov 14 21:00

Press Release: RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

Dow JonesNov 14 21:00

RenovoRx | 10-Q: Quarterly report

SECNov 14 05:23 · Announcements